MiR-550a-3-5p was found to directly target YAP to inhibit its expression, and overexpression of miR-550a-3-5p sensitized vemurafenib-resistant colon cancer and melanoma cells to vemurafenib [61]. Here, YAP1 is linked to colonic neoplasm.